Affordable Access

Access to the full text

Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK

Authors
  • Weidlich, Diana1
  • Andersson, Fredrik L.2, 3
  • Oelke, Matthias4
  • Drake, Marcus John5
  • Jonasson, Aino Fianu6
  • Guest, Julian F.1, 7
  • 1 Catalyst Health Economics Consultants, 34b High Street, Northwood, Middlesex, HA6 1BN, UK , Northwood (United Kingdom)
  • 2 Ferring Pharmaceuticals, Copenhagen, Denmark , Copenhagen (Denmark)
  • 3 Linköping University, Center for Medical Technology Assessment (CMT), Linköping, Sweden , Linköping (Sweden)
  • 4 Hanover Medical School, Department of Urology, Hannover, Germany , Hannover (Germany)
  • 5 Bristol Urological Institute, Bristol, UK , Bristol (United Kingdom)
  • 6 Karolinska Institutet, Division of Obstetrics and Gynaecology, CLINTEC, Stockholm, Sweden , Stockholm (Sweden)
  • 7 King’s College, Faculty of Life Sciences and Medicine, London, UK , London (United Kingdom)
Type
Published Article
Journal
The European Journal of Health Economics
Publisher
Springer Berlin Heidelberg
Publication Date
Sep 27, 2016
Volume
18
Issue
6
Pages
761–771
Identifiers
DOI: 10.1007/s10198-016-0826-x
Source
Springer Nature
Keywords
License
Green

Abstract

ObjectiveOur aim was to estimate the prevalence-based cost of illness imposed by nocturia (≥2 nocturnal voids per night) in Germany, Sweden, and the UK in an average year.MethodsInformation obtained from a systematic review of published literature and clinicians was used to construct an algorithm depicting the management of nocturia in these three countries. This enabled an estimation of (1) annual levels of healthcare resource use, (2) annual cost of healthcare resource use, and (3) annual societal cost arising from presenteeism and absenteeism attributable to nocturia in each country.ResultsIn an average year, there are an estimated 12.5, 1.2, and 8.6 million patients ≥20 years of age with nocturia in Germany, Sweden, and the UK, respectively. In an average year in each country, respectively, these patients were estimated to have 13.8, 1.4, and 10.0 million visits to a family practitioner or specialist, ~91,000, 9000, and 63,000 hospital admissions attributable to nocturia and 216,000, 19,000, and 130,000 subjects were estimated to incur a fracture resulting from nocturia. The annual direct cost of healthcare resource use attributable to managing nocturia was estimated to be approximately €2.32 billion in Germany, 5.11 billion kr (€0.54 billion) in Sweden, and £1.35 billion (€1.77 billion) in the UK. The annual indirect societal cost arising from both presenteeism and absenteeism was estimated to be approximately €20.76 billion in Germany and 19.65 billion kr (€2.10 billion) in Sweden. In addition, in the UK, the annual indirect cost due to absenteeism was an estimated £4.32 billion (€5.64 billion).ConclusionsNocturia appears to impose a substantial socioeconomic burden in all three countries. Clinical and economic benefits could accrue from an increased awareness of the impact that nocturia imposes on patients, health services, and society as a whole.

Report this publication

Statistics

Seen <100 times